PRKG1 and hydrops fetalis: Activation of PKG has emerged as a clinical strategy for the treatment of HF, with cGMP-augmenting medications, such as nitrates (3, 47), neprilysin inhibitors (4), and guanylate cyclase stimulators (5), demonstrating efficacy in HF with reduced ejection fraction.